Consistent with previous studies, this suggests that t(8;21) and inv(16) may not simply be classified using the same risk stratification approach as non‐CBF‐AML, and new, more scientifically‐based risk stratification methods are needed.19 The gene discussed is CEBPZ; the disease is acute myeloid leukemia.